AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06180395 — intervention group
Intervention type: OTHER
Intervention: Group 2
Description: consisted of 38 children with CP classified to level IV and V according to GMFCS. then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL).
Study NCT04691492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friend-Based Motivational Interview
Description: The intervention will use Motivational Interviewing's (MI) collaborative conversation style for strengthening commitment to change, to motivate and prepare women to work together to reduce Sexual Assault (SA) risk. This intervention will target ways that the friend dyad may support, encourage, and share responsibility with one another in protecting against SA. The Friend-based MI (FMI) will then use the responsibility and relationship of friends as a framework to foster collaborative efforts to increase readiness and decrease barriers to helping behavior. As part of this, the FMI will focus on the identification and implementation of skills friends can use to help one another prevent sexual assault. FMI will include a focused discussion of the ways drinking may impede helping efforts. Moreover, the FMI will encourage women to identify personal, specific strategies for reducing the effects of alcohol on helping.
Study NCT05397938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT103
Description: JMT103, subcutaneous injection, once every 6 months (Q6M)
Study NCT05397938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate sodium
Description: Alendronate sodium tablet, once every week (QW)
Study NCT05397938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JMT103 placebo
Description: JMT103 placebo, subcutaneous injection, once every 6 months (Q6M)
Study NCT05397938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate sodium placebo
Description: Alendronate sodium tablet placebo, once every week (QW)
Study NCT06343688 — intervention group
Intervention type: OTHER
Intervention: Assessment of Balance and Lower Extremity Gross Motor Function with and without DAFO
Description: Measurements will be conducted with the child's custom-made DAFO (Dynamic Ankle-Foot Orthosis) and barefoot.
Study NCT05429944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Relearning Program
Description: The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
Study NCT05429944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: The techniques administered included Rhythmic Initiation, Slow Reversal and Agonistic Reversal.~The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
Study NCT05429944 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
Study NCT05723796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasal endoscopy
Description: nasal endoscopy and mucosal biopsy
Study NCT05729854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure ( traditional and complementary medicine)
Description: Acupressure will be applied to the shoulders, hands and legs of the women in the experimental group by the researcher.
Study NCT04541264 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: radiomic of chest CT
Description: radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.
Study NCT04908540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini-screw Assissted Rapid Palatal Expansion
Description: Mini-screw assissted RPE will be the main intervention in the two comparative groups. In the control (group A) will be used with its conventional activation protocol. While in experimental (group B) will be used with ALT-RAMEC protocol.
Study NCT04908540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-screw Assissted Rapid Palatal Expansion
Description: Mini-screw assissted RPE will be the main intervention in the two comparative groups. In the control (group A) will be used with its conventional activation protocol. While in experimental (group B) will be used with ALT-RAMEC protocol.
Study NCT05468385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation via tragus
Description: The device will send stimulus intensity of around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
Study NCT05468385 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation via earlobe
Description: The device will send stimulus intensity of around 0.5mA via the earlobe in the left ear (based on participants' subjective reports), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
Study NCT06447285 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SensoDetect BERA technology
Description: All recruited participants are to be tested using SensoDetect's patented technology. All tests shall be performed in a quiet and darkened room. Participants will be asked to be comfortably seated in an armchair in a resting position (part 1 only). Surface electrodes will then be attached to the skin over the mastoid bones behind the left and right ear, with a ground electrode on one arm. Two reference electrodes will also be placed on the forehead. Before each test session, the procedure shall be fully explained to the test subject or parents.~The subjects will then be instructed to relax with their eyes closed and are permitted to fall asleep (with modifications in part 3). The test will require no active participation other than being subjected to sound stimulation. The subjects will be tested one at a time, and the duration of the testing procedure will be 15 min.
Study NCT05382455 — intervention group
Intervention type: OTHER
Intervention: Delphi Questionnaire
Description: An invitation email, including a link to the survey, will be sent to the panel of experts in Ai in healthcare.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the AI reporting standards in systematic reviews and objectively identify critical aspects of reporting methodology and results.~In subsequent surveys, the expert panel will evaluate the modified criteria using a 1 to 5-point Likert scale with space provided for suggested edits and comments. Multiple rounds will be conducted until consensus is reached. After each round of Likert responses, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed.
Study NCT05831540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in focus group
Study NCT05831540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Undergo training to use CDS tool
Study NCT04619862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: See arm descriptions
Study NCT05831540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare Activity
Description: Utilize CDS tool
Study NCT05831540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study NCT06491576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGT-002
Description: taking the study drug orally
Study NCT04619862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm descriptions
Study NCT04827251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coffee
Description: Participants will receive Nespresso coffee maker Essenza model. The coffee Nespresso blend voluto will be provided (caffeinated and decaffeinated). The patients will have to take four cups of espresso per day (three cups a day for patients aged 65 and over).
Study NCT06491576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taking the placebo orally
Study NCT05346640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cionic Neural Sleeve
Description: Adaptive, functional electrical stimulation
Study NCT04659096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION537
Description: ION537 will be administered by IV injection.
Study NCT04920825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sacha Inchi Oil softgel supplement
Description: A twice daily supplementation of Sacha Inchi Oil softgel for 12 weeks
Study NCT04920825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil softgel
Description: A twice daily supplementation of Corn Oil softgel for 12 weeks (Placebo)
Study NCT04831619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)
Description: A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).
Study NCT06480461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGN-R09b
Description: This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.
Study NCT06599073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RescueDoppler
Description: Continuous hands-free Doppler ultrasound of the carotid artery during cardiac arrest
Study NCT06599073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rescue
Description: RescueDoppler patch with probe is attached on the left side of the neck during the cardiac arrest. Operative health personell are blinded for the velocity curves that are post-processed by the research team after the cardiac arrest and synchronised with ECG.
Study NCT04846868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iclepertin
Description: Iclepertin
Study NCT04846868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05293314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: An exhaled breath test
Description: All exhaled breath samples were collected by trained investigators following the same protocol. All participants fasted for at least 6 hours before breath collection. To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection. Exhaled breath was collected in Tedlar air bags (DuPont de Nemours). The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times. Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags. A total of 1000 mL of exhaled breath was collected from each participant. Breath sample detection was based on the HPPI-TOFMS platform.
Study NCT05059522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: oral
Study NCT05374083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using autogenous demineralized dentin block graft
Description: Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by hydrochloric acid (HCL) acid and inserted as demineralized dentin block graft in the socket
Study NCT05374083 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using particulate deproteinized bovine bone graft
Description: Atraumatic extraction of non restorable tooth, then the socket will be packed by particulate deproteinized bovine bone
Study NCT06479395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Endurance and Limb Strengthening (PEDALS) program
Description: Participants will perform pediatric endurance and limb strengthening (PEDALS) program. The stationary cycling intervention will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. The longer session duration is designed to allow adequate rest intervals between set (1-3 minutes). A generalized stretching program will be performed prior to cycling for mental relaxation for 6-7 minutes. Ankle-foot orthosis if used for walking. Each 60 minutes cycling session will be divided into 2 phases: (1) lower-extremity strengthening and (2) cardiorespiratory endurance.
Study NCT06479395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task-Oriented Training (TOT)
Description: The experimental protocol consists of task-oriented training program (TOT) .it will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. Before each training session, there will be a warm-up period with 5 to 10 minutes of dynamic activities (e.g., jogging). After training, there will be a cool down period with 5 to 10 minutes of dynamic stretching exercises. In addition to rest intervals. after training session, there will be a 48-hour rest interval to prevent muscle fatigue and injury.
Study NCT06438627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPC combined with Apatinib and Camrelizumab
Description: Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab
Study NCT06438627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP Combined With Camrelizumab
Description: Gemcitabine, Cisplatin regimen Combined With Camrelizumab
Study NCT06396390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progestin
Description: In this regimen, Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day. The patient's dosage will be tailored based on their BMI, AMH value, and the number of follicles observed during the ultrasound examination on the 2nd day of the menstrual cycle. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
Study NCT06396390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: In this regimen, Cetrorelix (Cetrotide©, 250 mcg/mL, Pierre Fabre Medicament Production, Idron, France) 1x1 SC will be started on day 7 of menstrual cycle and will be continued until the trigger day. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
Study NCT06126419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose Insulin Therapy
Description: A baseline blood glucose value will be obtained. Two units of insulin will be administered IV if the blood glucose is > mmol/L. An insulin infusion of 0.12 units/kg/hr will be started. Ten minutes after starting the insulin, and when the blood glucose is \< 6 mmol/L, dextrose 20% supplemented with phosphate (30 mmol/L) will be infused. Blood glucose levels will be measured every 15 minutes, and the dextrose infusion rate adjusted to maintain glycemic levels between 4 and 6 mmol/L for a duration of 6 hours. At the end of the 6 hour period, the insulin will be stopped and the dextrose will be weaned off.
Study NCT05711329 — intervention group
Intervention type: OTHER
Intervention: Accuracy
Description: We will validate the accuracy of the method proposed by the SFAR to detect OSA patients via videoconference (in comparison with the results of the PSG).
Study NCT06171048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection
Study NCT05059522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatanib
Description: oral
Study NCT05059522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: oral
Study NCT05059522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV (intravenous) infusion
Study NCT05059522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: oral
Study NCT04893330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: pepticate syneo
Description: follow up of pepticate syneo for one month
Study NCT05059522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP 001
Description: IT (intratumoral) or SC (subcutaneous)
Study NCT05059522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: IV infusion
Study NCT05059522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF04518600
Description: IV infusion
Study NCT05319951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Salts power (iii)
Description: Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
Study NCT05319951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with white granulated sugar
Description: Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
Study NCT05319951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
Study NCT05632133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 50 MG Oral Tablet
Description: We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
Study NCT05632133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
Study NCT05592470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Description: Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
Study NCT06164795 — intervention group
Intervention type: DRUG
Intervention: Zoledronate
Description: intravenous infusion
Study NCT06164795 — intervention group
Intervention type: DRUG
Intervention: Denosumab
Description: subcutaneous injection
Study NCT06164795 — intervention group
Intervention type: DRUG
Intervention: Teriparatide
Description: subcutaneous injection
Study NCT06164795 — intervention group
Intervention type: DRUG
Intervention: Romosozumab
Description: subcutaneous injection
Study NCT05544825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ice plant group
Description: Ice plant extract 2,000 mg/day for 12 weeks
Study NCT05544825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 2,000 mg/day for 12 weeks
Study NCT04852601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ToolboxDetect
Description: The clinician or staff member will identify the patient by either scanning a barcode or entering his/her name, age and medical record number on an administrative screen (allowing for proper routing of test results). After completing the test, a 'submit' button will automatically generate a secure HL7 message, sharing 1) a binary classification of the results ('impaired cognition' or 'normal function'), 2) the quantitative ToolboxDetect score, and 3) brief clinical decision support to rule out any reversible causes. These results will be linked to a discrete, queriable, Epic SmartData element. As patients undergo multiple AWVs over time, ToolboxDetect quantitative scores will be displayed in Epic Synopsis Activity, a graphical display that can visualize trend data (e.g. patient vitals) and calculate a percentage change from the prior year. This will allow a clinician to establish a patient's own baseline (instead of using normative data only) for reference.
Study NCT06671054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189, 40 mg
Description: AP1189 tablets for oral use
Study NCT06671054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189, 70 mg
Description: AP1189 tablets for oral use
Study NCT06175663 — intervention group
Intervention type: DRUG
Intervention: Antihypertensive medication withdrawal
Description: To determine if high blood pressure is caused by an overproduction of aldosterone in the adrenal gland (i.e. primary hyperaldosteronism), the plasma aldosterone/renin ratio (ARR) can be determined. Because many common hypertensive drugs are known to interfere with this ratio, patients often have to discontinue drugs prior to screening or switch to drugs that are known not to affect ARR (i.e. doxazosin, verapamil, diltiazem, hydralazine). Drugs have to be stopped for at least four weeks (for mineralocorticoid receptor antagonists) or two weeks (for diuretics, Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs)). This often leads to a temporary increase in blood pressure. After diagnostics are completed, medication is adjusted accordingly and blood pressure levels drop again.